.jpeg)
2026-08-13 04:02:58
Asciminib (brand name SCEMBLIX) is the first STAMP-class targeted therapy for chronic myeloid leukemia. This article clarifies nomenclature consistency, strict fasting requirements, missed-dose protocols, and safety monitoring essentials to help patients avoid medication errors and optimize therapeutic outcomes.
2026-08-12 04:11:20
Enasidenib (brand name IDHIFA) is an oral, selective IDH2 inhibitor indicated for adult patients with relapsed or refractory acute myeloid leukemia (AML) harboring an IDH2 mutation. This article covers its indications, dosing, adverse effects, mechanism of action, storage, and special-population considerations.
2026-08-11 06:06:06
Midostaurin and gilteritinib are both FLT3-targeted agents but differ fundamentally in selectivity, indications, and treatment phase. This article systematically compares their mechanisms, clinical roles, and appropriate use contexts in precision AML management.
2026-08-10 06:39:28
Belumosudil (Rezurock) is a selective ROCK2 inhibitor approved for chronic graft-versus-host disease. This article explains the expected timeline, efficacy assessment, and realistic goals when treating pulmonary cGVHD.
2026-08-07 06:49:51
Tazemetostat is the world's first approved oral EZH2 methyltransferase inhibitor, targeting epigenetic dysregulation in follicular lymphoma and epithelioid sarcoma. This article provides a comprehensive overview of its mechanism of action, approved indications, efficacy data, standard starting and maintenance dosing, dose modification protocols, and the critical safety alert regarding its global market withdrawal in March 2026 due to secondary hematologic malignancy risk.
2026-08-06 06:43:18
Ponatinib is a third-generation tyrosine kinase inhibitor designed to target the BCR::ABL1 oncoprotein, offering a precision therapy option for Philadelphia chromosome-positive leukemias, particularly in patients harboring the T315I mutation or exhibiting resistance to prior TKIs.
2026-08-04 03:16:47
Avatrombopag is an oral small-molecule thrombopoietin receptor agonist (TPO-RA) widely used in the management of chronic liver disease-associated thrombocytopenia and immune thrombocytopenia (ITP). This article provides a comprehensive overview of its composition, mechanism of action, indications, precise medication criteria, and adverse reaction management.
2026-08-03 05:08:22
A comprehensive overview of the standard dosing regimen for the EZH2 inhibitor tazemetostat, bioequivalence of the Laos generic formulation, cross-comparison with alternative therapies, and critical safety guidance following the global market withdrawal.
2026-07-30 05:15:44
A systematic review of the oral TPO-RA avatrombopag covering its mechanism of action, three approved indications, short-course and long-term maintenance regimens, and comprehensive efficacy and safety comparisons with eltrombopag and hetrombopag to support individualized precision treatment.
2026-07-30 03:13:41
A comprehensive analysis of venetoclax, the world's first oral BCL-2 inhibitor, covering its pharmacological mechanism, clinical applications in CLL and AML, and strategic considerations for choosing between originator and generic formulations.
2026-07-29 06:14:14
Hetrombopag and avatrombopag are both oral thrombopoietin receptor agonists (TPO-RAs) used to treat thrombocytopenia. This article systematically compares their mechanisms of action, approved indications, dosing regimens, and safety warnings to support informed clinical decision-making.
2026-07-23 02:43:41
In July 2026, the FDA approved subcutaneous isatuximab (Sarclisa) for multiple myeloma across three indications spanning newly diagnosed to relapsed/refractory disease. This article reviews pivotal trial data, recommended dosing, and key safety warnings.
